Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:13 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Arunjyoti Bio Ventures Ltd operates in the Trading & Distributors industry, with a current share price of ₹12.4 and a market capitalization of ₹232 Cr. The company experienced a significant revenue increase, recording sales of ₹1.74 Cr for the fiscal year ending March 2023, which rose to ₹20.43 Cr in March 2024 and is reported at ₹27.88 Cr for March 2025. The quarterly sales figures demonstrate a progressive growth trajectory, from ₹0.48 Cr in December 2022 to ₹8.70 Cr in March 2024. However, the first quarter of FY 2025 reported a dip to ₹5.28 Cr before recovering to ₹8.71 Cr in June 2025. This volatility indicates a need for stability in revenue generation. Overall, the sales growth reflects a transition from previous years of minimal sales, positioning the company towards better operational performance and market presence.
Profitability and Efficiency Metrics
The profitability metrics for Arunjyoti Bio Ventures Ltd show a mixed performance. The company reported a negative net profit of ₹1.16 Cr for FY 2025, despite an increase in operating profit margins (OPM), which stood at 41.33% in June 2025. The operating profit for the same period was ₹3.60 Cr, indicating effective cost management and operational efficiency. However, the net profit margin remains concerning, recorded at -6.53% in March 2025. The interest coverage ratio (ICR) of 2.04x suggests adequate ability to cover interest obligations, but the company has shown inconsistent profit before tax, fluctuating from ₹0.17 Cr in March 2023 to -₹1.30 Cr in March 2024. These figures indicate that while the company is experiencing improved revenue and operational efficiency, profitability remains a significant challenge and indicates potential risks in sustainable growth.
Balance Sheet Strength and Financial Ratios
Arunjyoti Bio Ventures Ltd reported a total asset value of ₹59.62 Cr for the fiscal year ending March 2025, with liabilities amounting to ₹59.62 Cr, reflecting a balanced sheet position. The reserves have risen to ₹13.74 Cr, contrasting with previous years of negative reserves, which is a positive indicator of retained earnings and financial health. The long-term debt to equity ratio stood at 0.64, suggesting manageable leverage levels, although borrowings of ₹26.21 Cr could pose risks if not effectively managed. The current ratio of 2.80 and quick ratio of 2.30 indicate strong liquidity positions, allowing it to cover short-term obligations comfortably. However, the price-to-book value (P/BV) ratio of 7.71x raises concerns about valuation, potentially indicating overvaluation compared to industry norms, which typically range lower.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Arunjyoti Bio Ventures Ltd reveals a significant shift in promoter and public ownership. As of March 2025, promoters hold 47.64% of the shares, down from 61.79% in June 2024, indicating a potential dilution of control or strategic changes. The public’s stake has increased to 52.36%, suggesting growing investor interest and confidence in the company. The number of shareholders surged to 5,321, reflecting broader participation in the company’s equity. This diversification could enhance market stability, but the decline in promoter shareholding may raise questions about long-term strategic commitment. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) indicates a lack of institutional confidence, which could impact stock liquidity and valuation moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Arunjyoti Bio Ventures Ltd has the potential for growth given its recent revenue trends and improved operational efficiencies. However, profitability remains a significant concern, with risks stemming from fluctuating net profits and a high P/BV ratio. The company’s ability to maintain sales momentum while controlling costs will be critical. Additionally, the changing shareholding pattern could affect investor confidence and strategic direction. To enhance its market position, the company may need to develop clearer strategies for sustainable profitability and possibly attract institutional investors to stabilize its share price. If the company successfully addresses its profitability challenges and maintains its revenue growth, it could emerge as a stronger player in the Trading & Distributors industry; otherwise, it may face ongoing volatility and investor scrutiny.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Arunjyoti Bio Ventures Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 63.3 Cr. | 3.30 | 5.59/3.20 | 42.2 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 13.3 Cr. | 15.1 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 6.58 Cr. | 72.3 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 103 Cr. | 50.4 | 54.5/10.2 | 115 | 15.1 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 108 Cr. | 97.0 | 174/84.4 | 15.2 | 30.6 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 10,708.34 Cr | 160.14 | 89.71 | 120.92 | 0.40% | 15.37% | 8.86% | 7.74 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.48 | 1.26 | 2.80 | 3.14 | 5.79 | 8.70 | 10.10 | 6.35 | 6.15 | 5.28 | 8.71 |
| Expenses | 0.04 | 0.02 | 0.44 | 1.10 | 2.74 | 3.49 | 3.97 | 7.46 | 6.56 | 5.57 | 5.81 | 4.94 | 5.11 |
| Operating Profit | -0.04 | -0.02 | 0.04 | 0.16 | 0.06 | -0.35 | 1.82 | 1.24 | 3.54 | 0.78 | 0.34 | 0.34 | 3.60 |
| OPM % | 8.33% | 12.70% | 2.14% | -11.15% | 31.43% | 14.25% | 35.05% | 12.28% | 5.53% | 6.44% | 41.33% | ||
| Other Income | 0.00 | 0.10 | 0.00 | 0.00 | 0.01 | 0.07 | 0.00 | -0.04 | 0.10 | 0.11 | 0.06 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | -0.01 | 0.01 | 0.57 | 0.71 | 0.80 | 0.67 | 0.67 | 0.65 | 0.59 | 0.62 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 0.67 | 0.81 | 0.72 | 0.74 | 0.78 | 0.80 | 0.82 |
| Profit before tax | -0.04 | 0.08 | 0.04 | 0.17 | 0.06 | -1.39 | 0.44 | -0.41 | 2.25 | -0.52 | -1.03 | -1.04 | 2.17 |
| Tax % | 0.00% | 12.50% | 25.00% | 0.00% | 16.67% | -0.72% | 163.64% | -407.32% | 24.89% | -21.15% | 7.77% | 91.35% | -8.76% |
| Net Profit | -0.04 | 0.07 | 0.03 | 0.17 | 0.04 | -1.37 | -0.28 | 1.26 | 1.69 | -0.41 | -1.12 | -1.99 | 2.36 |
| EPS in Rs | -0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.07 | -0.02 | 0.07 | 0.09 | -0.02 | -0.06 | -0.11 | 0.13 |
Last Updated: August 19, 2025, 11:20 pm
Below is a detailed analysis of the quarterly data for Arunjyoti Bio Ventures Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 8.71 Cr.. The value appears strong and on an upward trend. It has increased from 5.28 Cr. (Mar 2025) to 8.71 Cr., marking an increase of 3.43 Cr..
- For Expenses, as of Jun 2025, the value is 5.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.94 Cr. (Mar 2025) to 5.11 Cr., marking an increase of 0.17 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.60 Cr.. The value appears strong and on an upward trend. It has increased from 0.34 Cr. (Mar 2025) to 3.60 Cr., marking an increase of 3.26 Cr..
- For OPM %, as of Jun 2025, the value is 41.33%. The value appears strong and on an upward trend. It has increased from 6.44% (Mar 2025) to 41.33%, marking an increase of 34.89%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.59 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.80 Cr. (Mar 2025) to 0.82 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.17 Cr.. The value appears strong and on an upward trend. It has increased from -1.04 Cr. (Mar 2025) to 2.17 Cr., marking an increase of 3.21 Cr..
- For Tax %, as of Jun 2025, the value is -8.76%. The value appears to be improving (decreasing) as expected. It has decreased from 91.35% (Mar 2025) to -8.76%, marking a decrease of 100.11%.
- For Net Profit, as of Jun 2025, the value is 2.36 Cr.. The value appears strong and on an upward trend. It has increased from -1.99 Cr. (Mar 2025) to 2.36 Cr., marking an increase of 4.35 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.13. The value appears strong and on an upward trend. It has increased from -0.11 (Mar 2025) to 0.13, marking an increase of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.08 | 0.00 | 0.21 | 39.27 | 0.05 | 3.72 | 6.74 | 5.51 | 2.94 | 1.74 | 20.43 | 27.88 | 26.49 |
| Expenses | 0.07 | 0.02 | 0.27 | 39.03 | 0.28 | 3.68 | 6.61 | 5.41 | 3.14 | 1.57 | 17.65 | 22.86 | 21.43 |
| Operating Profit | 0.01 | -0.02 | -0.06 | 0.24 | -0.23 | 0.04 | 0.13 | 0.10 | -0.20 | 0.17 | 2.78 | 5.02 | 5.06 |
| OPM % | 12.50% | -28.57% | 0.61% | -460.00% | 1.08% | 1.93% | 1.81% | -6.80% | 9.77% | 13.61% | 18.01% | 19.10% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 | 0.04 | 0.28 | 0.19 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 2.11 | 2.59 | 2.53 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 3.05 | 3.14 |
| Profit before tax | 0.00 | -0.03 | -0.07 | 0.24 | -0.24 | 0.04 | 0.13 | 0.09 | 0.08 | 0.16 | -1.30 | -0.34 | -0.42 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 0.00% | 23.08% | 22.22% | 25.00% | 25.00% | -73.08% | 435.29% | ||
| Net Profit | 0.00 | -0.04 | -0.07 | 0.20 | -0.25 | 0.04 | 0.11 | 0.07 | 0.06 | 0.12 | -0.35 | -1.82 | -1.16 |
| EPS in Rs | 0.00 | -0.00 | -0.00 | 0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | -0.02 | -0.10 | -0.06 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -75.00% | 385.71% | -225.00% | 116.00% | 175.00% | -36.36% | -14.29% | 100.00% | -391.67% | -420.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 460.71% | -610.71% | 341.00% | 59.00% | -211.36% | 22.08% | 114.29% | -491.67% | -28.33% |
Arunjyoti Bio Ventures Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 112% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -189% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 117% |
| 3 Years: | 115% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -8% |
| 3 Years: | -10% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:24 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 18.64 | 18.64 |
| Reserves | -0.19 | -0.23 | -0.30 | -0.10 | -0.34 | -0.30 | -0.19 | -0.13 | -0.07 | 0.04 | -0.30 | 13.74 | 15.24 |
| Borrowings | 0.00 | 0.00 | 0.04 | 0.19 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27 | 51.40 | 26.21 | 24.13 |
| Other Liabilities | 0.11 | 0.13 | 0.36 | 17.70 | 8.36 | 3.71 | 4.02 | 2.77 | 0.09 | 1.53 | 0.82 | 1.03 | 1.08 |
| Total Liabilities | 1.99 | 1.97 | 2.17 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 35.91 | 53.99 | 59.62 | 59.09 |
| Fixed Assets | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.50 | 43.33 | 46.92 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.19 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 1.96 | 1.95 | 2.16 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 16.72 | 13.49 | 16.29 | 12.17 |
| Total Assets | 1.99 | 1.97 | 2.17 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 35.91 | 53.99 | 59.62 | 59.09 |
Below is a detailed analysis of the balance sheet data for Arunjyoti Bio Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.64 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.64 Cr..
- For Reserves, as of Sep 2025, the value is 15.24 Cr.. The value appears strong and on an upward trend. It has increased from 13.74 Cr. (Mar 2025) to 15.24 Cr., marking an increase of 1.50 Cr..
- For Borrowings, as of Sep 2025, the value is 24.13 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 26.21 Cr. (Mar 2025) to 24.13 Cr., marking a decrease of 2.08 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.03 Cr. (Mar 2025) to 1.08 Cr., marking an increase of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 59.09 Cr.. The value appears to be improving (decreasing). It has decreased from 59.62 Cr. (Mar 2025) to 59.09 Cr., marking a decrease of 0.53 Cr..
- For Fixed Assets, as of Sep 2025, the value is 46.92 Cr.. The value appears strong and on an upward trend. It has increased from 43.33 Cr. (Mar 2025) to 46.92 Cr., marking an increase of 3.59 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 12.17 Cr.. The value appears to be declining and may need further review. It has decreased from 16.29 Cr. (Mar 2025) to 12.17 Cr., marking a decrease of 4.12 Cr..
- For Total Assets, as of Sep 2025, the value is 59.09 Cr.. The value appears to be declining and may need further review. It has decreased from 59.62 Cr. (Mar 2025) to 59.09 Cr., marking a decrease of 0.53 Cr..
However, the Borrowings (24.13 Cr.) are higher than the Reserves (15.24 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.01 | -0.02 | -0.10 | 0.05 | -0.42 | 0.04 | 0.13 | 0.10 | -0.20 | -32.10 | -48.62 | -21.19 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 821.25 | 677.86 | 159.68 | 32,923.00 | 231.56 | 144.59 | 121.89 | 67.04 | 163.62 | 48.77 | 51.97 | |
| Inventory Days | 0.00 | 61.61 | 1.80 | 2.34 | 0.00 | 214.13 | 125.52 | 182.85 | ||||
| Days Payable | 245.27 | 130.66 | 102.39 | 0.00 | 16.71 | 0.00 | ||||||
| Cash Conversion Cycle | 821.25 | 677.86 | 159.68 | 32,923.00 | 47.90 | 15.73 | 21.84 | 67.04 | 377.75 | 157.59 | 234.82 | |
| Working Capital Days | 319.38 | 52.14 | 2.14 | -22,703.00 | -6.87 | -40.07 | -23.85 | 122.91 | 834.89 | 109.88 | 116.78 | |
| ROCE % | 0.00% | -1.61% | -3.84% | 12.09% | -11.27% | 2.17% | 7.12% | 5.24% | 4.06% | 0.93% | 1.85% | 4.03% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.10 | -1.68 | 0.56 | 0.27 | 0.33 |
| Diluted EPS (Rs.) | -0.10 | -1.68 | 0.56 | 0.27 | 0.33 |
| Cash EPS (Rs.) | 0.06 | 8.04 | 0.56 | 0.27 | 0.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.74 | 8.53 | 10.22 | 9.66 | 9.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.74 | 8.53 | 10.22 | 9.66 | 9.39 |
| Revenue From Operations / Share (Rs.) | 1.50 | 98.66 | 8.38 | 14.35 | 26.62 |
| PBDIT / Share (Rs.) | 0.28 | 13.55 | 0.78 | 0.37 | 0.45 |
| PBIT / Share (Rs.) | 0.12 | 3.83 | 0.78 | 0.37 | 0.45 |
| PBT / Share (Rs.) | -0.01 | -6.27 | 0.76 | 0.36 | 0.44 |
| Net Profit / Share (Rs.) | -0.09 | -1.68 | 0.56 | 0.27 | 0.32 |
| PBDIT Margin (%) | 18.98 | 13.73 | 9.38 | 2.59 | 1.70 |
| PBIT Margin (%) | 8.06 | 3.88 | 9.38 | 2.59 | 1.70 |
| PBT Margin (%) | -1.22 | -6.35 | 9.09 | 2.55 | 1.67 |
| Net Profit Margin (%) | -6.53 | -1.70 | 6.73 | 1.89 | 1.23 |
| Return on Networth / Equity (%) | -5.62 | -19.74 | 5.52 | 2.81 | 3.50 |
| Return on Capital Employeed (%) | 4.13 | 1.62 | 0.47 | 3.84 | 4.82 |
| Return On Assets (%) | -3.05 | -0.64 | 0.32 | 2.68 | 1.45 |
| Long Term Debt / Equity (X) | 0.64 | 26.38 | 15.26 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.79 | 28.73 | 15.26 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.49 | 0.45 | 0.09 | 0.87 | 1.04 |
| Current Ratio (X) | 2.80 | 2.24 | 3.64 | 11.67 | 1.16 |
| Quick Ratio (X) | 2.30 | 1.66 | 3.06 | 11.67 | 1.15 |
| Inventory Turnover Ratio (X) | 10.04 | 0.00 | 0.00 | 221.57 | 0.00 |
| Interest Coverage Ratio (X) | 2.04 | 1.34 | 32.67 | 78.09 | 59.74 |
| Interest Coverage Ratio (Post Tax) (X) | 0.29 | 0.83 | 24.43 | 58.04 | 44.47 |
| Enterprise Value (Cr.) | 274.59 | 62.47 | 69.78 | 5.17 | 0.61 |
| EV / Net Operating Revenue (X) | 9.85 | 3.06 | 40.21 | 1.74 | 0.11 |
| EV / EBITDA (X) | 51.87 | 22.26 | 428.45 | 67.13 | 6.52 |
| MarketCap / Net Operating Revenue (X) | 8.95 | 0.57 | 21.63 | 1.74 | 0.25 |
| Price / BV (X) | 7.71 | 6.68 | 17.74 | 2.59 | 0.73 |
| Price / Net Operating Revenue (X) | 8.95 | 0.57 | 21.63 | 1.74 | 0.25 |
| EarningsYield | -0.01 | -0.02 | 0.00 | 0.01 | 0.04 |
After reviewing the key financial ratios for Arunjyoti Bio Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has increased from -1.68 (Mar 24) to -0.10, marking an increase of 1.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has increased from -1.68 (Mar 24) to -0.10, marking an increase of 1.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 3. It has decreased from 8.04 (Mar 24) to 0.06, marking a decrease of 7.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.74. It has decreased from 8.53 (Mar 24) to 1.74, marking a decrease of 6.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.74. It has decreased from 8.53 (Mar 24) to 1.74, marking a decrease of 6.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.50. It has decreased from 98.66 (Mar 24) to 1.50, marking a decrease of 97.16.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 2. It has decreased from 13.55 (Mar 24) to 0.28, marking a decrease of 13.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.12. This value is within the healthy range. It has decreased from 3.83 (Mar 24) to 0.12, marking a decrease of 3.71.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.01. This value is below the healthy minimum of 0. It has increased from -6.27 (Mar 24) to -0.01, marking an increase of 6.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has increased from -1.68 (Mar 24) to -0.09, marking an increase of 1.59.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 13.73 (Mar 24) to 18.98, marking an increase of 5.25.
- For PBIT Margin (%), as of Mar 25, the value is 8.06. This value is below the healthy minimum of 10. It has increased from 3.88 (Mar 24) to 8.06, marking an increase of 4.18.
- For PBT Margin (%), as of Mar 25, the value is -1.22. This value is below the healthy minimum of 10. It has increased from -6.35 (Mar 24) to -1.22, marking an increase of 5.13.
- For Net Profit Margin (%), as of Mar 25, the value is -6.53. This value is below the healthy minimum of 5. It has decreased from -1.70 (Mar 24) to -6.53, marking a decrease of 4.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is -5.62. This value is below the healthy minimum of 15. It has increased from -19.74 (Mar 24) to -5.62, marking an increase of 14.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.13. This value is below the healthy minimum of 10. It has increased from 1.62 (Mar 24) to 4.13, marking an increase of 2.51.
- For Return On Assets (%), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has decreased from -0.64 (Mar 24) to -3.05, marking a decrease of 2.41.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 26.38 (Mar 24) to 0.64, marking a decrease of 25.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.79. This value is within the healthy range. It has decreased from 28.73 (Mar 24) to 0.79, marking a decrease of 27.94.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.49. It has increased from 0.45 (Mar 24) to 0.49, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 2.24 (Mar 24) to 2.80, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 2.30. This value exceeds the healthy maximum of 2. It has increased from 1.66 (Mar 24) to 2.30, marking an increase of 0.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 10.04. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 10.04, marking an increase of 10.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.04. This value is below the healthy minimum of 3. It has increased from 1.34 (Mar 24) to 2.04, marking an increase of 0.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 3. It has decreased from 0.83 (Mar 24) to 0.29, marking a decrease of 0.54.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.59. It has increased from 62.47 (Mar 24) to 274.59, marking an increase of 212.12.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.85. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 9.85, marking an increase of 6.79.
- For EV / EBITDA (X), as of Mar 25, the value is 51.87. This value exceeds the healthy maximum of 15. It has increased from 22.26 (Mar 24) to 51.87, marking an increase of 29.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.95. This value exceeds the healthy maximum of 3. It has increased from 0.57 (Mar 24) to 8.95, marking an increase of 8.38.
- For Price / BV (X), as of Mar 25, the value is 7.71. This value exceeds the healthy maximum of 3. It has increased from 6.68 (Mar 24) to 7.71, marking an increase of 1.03.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.95. This value exceeds the healthy maximum of 3. It has increased from 0.57 (Mar 24) to 8.95, marking an increase of 8.38.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to -0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arunjyoti Bio Ventures Ltd:
- Net Profit Margin: -6.53%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.13% (Industry Average ROCE: 15.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -5.62% (Industry Average ROE: 8.86%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.29
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 89.71)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -6.53%
Arunjyoti Bio Ventures Ltd: Intrinsic Value & Share Price Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | Door No.1-98/1/JSIC/6F/604-B, 6th Floor, Jain Sadhguru Capital Park, Madha Telangana 500081 | cenport@gmail.com https://www.abvl.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. PBN Murthy | Whole Time Director |
| Mr. Dathivik Pabbathi | Whole Time Director |
| Mr. Vishal Nadimpalli | Whole Time Director |
| Mrs. Dhanalakshmi Guntaka | Independent Director |
| Mr. Srikar Ranga | Independent Director |
| Mr. Vijaya Rama Lakshmana Murthy | Independent Director |
FAQ
What is the intrinsic value of Arunjyoti Bio Ventures Ltd?
Arunjyoti Bio Ventures Ltd's intrinsic value (as of 03 December 2025) is 2.38 which is 71.39% lower the current market price of 8.32, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 155 Cr. market cap, FY2025-2026 high/low of 21.0/5.05, reserves of ₹15.24 Cr, and liabilities of 59.09 Cr.
What is the Market Cap of Arunjyoti Bio Ventures Ltd?
The Market Cap of Arunjyoti Bio Ventures Ltd is 155 Cr..
What is the current Stock Price of Arunjyoti Bio Ventures Ltd as on 03 December 2025?
The current stock price of Arunjyoti Bio Ventures Ltd as on 03 December 2025 is 8.32.
What is the High / Low of Arunjyoti Bio Ventures Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arunjyoti Bio Ventures Ltd stocks is 21.0/5.05.
What is the Stock P/E of Arunjyoti Bio Ventures Ltd?
The Stock P/E of Arunjyoti Bio Ventures Ltd is .
What is the Book Value of Arunjyoti Bio Ventures Ltd?
The Book Value of Arunjyoti Bio Ventures Ltd is 1.82.
What is the Dividend Yield of Arunjyoti Bio Ventures Ltd?
The Dividend Yield of Arunjyoti Bio Ventures Ltd is 0.00 %.
What is the ROCE of Arunjyoti Bio Ventures Ltd?
The ROCE of Arunjyoti Bio Ventures Ltd is 4.03 %.
What is the ROE of Arunjyoti Bio Ventures Ltd?
The ROE of Arunjyoti Bio Ventures Ltd is 10.7 %.
What is the Face Value of Arunjyoti Bio Ventures Ltd?
The Face Value of Arunjyoti Bio Ventures Ltd is 1.00.